The Impact of Tralokinumab on Quality of Life and School in Patients Aged 12–17 With Atopic Dermatitis: Results from the Phase 3 ECZTRA 6 Trial. J of Skin 2022, 6 (6), s77. https://doi.org/10.25251/skin.6.supp.77.